CN103417966B - Hydrochloric acid aminolevulinic acid liniment and preparation technology thereof - Google Patents
Hydrochloric acid aminolevulinic acid liniment and preparation technology thereof Download PDFInfo
- Publication number
- CN103417966B CN103417966B CN201310374599.0A CN201310374599A CN103417966B CN 103417966 B CN103417966 B CN 103417966B CN 201310374599 A CN201310374599 A CN 201310374599A CN 103417966 B CN103417966 B CN 103417966B
- Authority
- CN
- China
- Prior art keywords
- liniment
- powder
- solvent
- radix
- filtrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940040145 liniment Drugs 0.000 title claims abstract description 26
- 239000000865 liniment Substances 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 238000005516 engineering process Methods 0.000 title abstract description 8
- BYAFJYYQCWOTAX-UHFFFAOYSA-N 2-amino-4-oxopentanoic acid;hydrochloride Chemical compound Cl.CC(=O)CC(N)C(O)=O BYAFJYYQCWOTAX-UHFFFAOYSA-N 0.000 title abstract 5
- 239000000843 powder Substances 0.000 claims abstract description 32
- 206010000496 acne Diseases 0.000 claims abstract description 30
- 239000002904 solvent Substances 0.000 claims abstract description 29
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims description 28
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000000706 filtrate Substances 0.000 claims description 18
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 11
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 9
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 9
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 241000195474 Sargassum Species 0.000 claims description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 230000001678 irradiating effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 235000009161 Espostoa lanata Nutrition 0.000 description 4
- 240000001624 Espostoa lanata Species 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229940055019 propionibacterium acne Drugs 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241000186427 Cutibacterium acnes Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 239000005030 aluminium foil Substances 0.000 description 2
- 230000003260 anti-sepsis Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ZLHFONARZHCSET-UHFFFAOYSA-N 5-aminolevulinic acid hydrochloride Chemical compound Cl.NCC(=O)CCC(O)=O ZLHFONARZHCSET-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010042928 Syringomyelia Diseases 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000013210 evaluation model Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000001329 hyperkeratotic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the medical technology filed and discloses a hydrochloric acid aminolevulinic acid liniment which is composed of a powder agent and a solvent. When the hydrochloric acid aminolevulinic acid liniment is used, the powder agent and the solvent are dissolved by matching with each other. The invention further discloses a preparation method of the hydrochloric acid aminolevulinic acid liniment. The prepared hydrochloric acid aminolevulinic acid liniment is good in effect of treating acne, free of toxic side effects, simple in manufacturing method and wide in application prospect.
Description
Technical field
The invention belongs to medical technical field, relate to a kind of 5-ALA liniment and preparation technology thereof.
Background technology
Acne is a kind of multifactorial disease, and its morbidity is main and sex hormone level, sebaceous gland are secreted in a large number, propionibacterium acnes propagation, the factor analysis such as the dyskeratosis of pilosebaceous duct and inflammation.Acne is apt to occur in hebetic masculinity and femininity, and male is slightly more than women, but women's morbidity is early than male.Have the teenager of 80-90% to suffer from acne, after adolescence, often can naturally go down or fully recover, indivedual patients also can extend to more than 30 years old.Although acne is the disease that has spontaneous recovery tendency, acne itself and acne treatment cause not in time
cicatrixcan have a strong impact on patient's quality of life, cause patient's stress and financial burden, need cause concern.Acne is apt to occur in buccal, forehead, buccal and nasolabial fold, is secondly chest, back and shoulder.The general no conscious sympton of acne lesions, can, with pain, be divided into acne, pimple, pustule and cyst tuberosity etc. when inflammation is obvious
Acne is an easily disease for recurrence, and the fluctuation of state of an illness weight own is indefinite.Affect acne factor a lot, single therapy is often difficult to receive good effect, need to take Comprehensive Treatment according to the state of an illness.First to adjust phychology, keep actively optimistic state; Eat less pungent greasy food and sweet food, these food all can stimulate fuel-displaced, increase the weight of acne; Eat vegetable and fruit more, keep free movement of the bowels also very important.In addition, select suitable facial cleansing agent and wetting agent according to skin type, and form good washing and protect custom, too not remove oils and fats and do not protect, cause skin too dry, skin barrier function is impaired, also can increase the weight of to a certain extent acne.Adhere to external medication when symptom is lighter, during severe symptoms, add oral drugs and control, to shorten the natural history of acne, reduce its probability that sequela occurs (pox prints and pox scar).External used medicine comprises tretinoin medicines and the lincomycin for the treatment of acne, benzoyl peroxide etc.Oral drugs: middle severe acne can Combined with Oral azithromycin etc. antibiotic medicine.Antibiotic controls inflammation rapidly effectively, but does not prevent the effect of recurrence.Severe acne can be taken Tai Ersi.Can adopt and start the method for drug administration of successively decreasing, or adopt the treatment of median dose position.Long-term taking antibiotic can produce larger drug resistance and toxic and side effects to body, and can not effect a radical cure acne.
5-ALA (ALAHCl) has another name called 5-ALA hydrochlorate, is the second filial generation photosensitizer of just having developed in recent years, is optical dynamic therapy medicine.In December, 2000, Gai Yaoyi U.S. official listing, is used for the treatment of face and the non-hyperkeratotic actinic keratosis of scalp.Meanwhile, the said firm started to treat with ALA-PDT the clinical trial of common acne in 1996, the existing II clinical trial phase that carrying out.Acne is a kind of dermatosis that affects 80% above adolescent, propionibacterium acne bacterium (Propionibacterium acnes) and sebum secretion play a major role in the morbidity of acne, present stage, primary treatment method was with the treatment of antibiotic and tretinoin medicine, but this bacterium is to antibiotic drug resistance gradually, and although tretinoin medicine is useful to the state of an illness, but having potential teratogenesis, is not very desirable.5-ALA liniment associating optical dynamic therapy is as the new treatment means of acne vulgaris, there is the features such as safe and effective, side effect is little, be a kind of very effective Therapeutic Method, in order to ensure people ' s health, to meet the demand growing to this medicine, we determine to develop this medicine.
Summary of the invention
The object of this invention is to provide a kind for the treatment of both the principal and secondary aspects of a disease, have no side effect, safe ready, cheap 5-ALA liniment.Its objective is for effectively treatment and prevention acne, the drug safety that overcomes prior art is poor, the easy defect such as recurrence of pigmentation and drug withdrawal.The present invention also provides the preparation technology of above-mentioned liniment.
For realizing above-mentioned purpose of the present invention, the technical solution used in the present invention is as follows:
A 5-ALA liniment, it is comprised of powder and solvent two parts, described powder is 354mg/ bottle, described solvent is 1.5ml/ bottle, during use by the two molten fitting over together.
Described powder is 5-ALA; Described solvent (1.5ml) is mixed by ethanol 672mg, sodium lauryl sulphate 5mg, PEG400 21mg, propylene glycol 49mg and pure water.
Preferably,
Described powder is that 5-ALA and compound Chinese medicine powder mix according to the weight ratio of 1:1; Described solvent (1.5ml) is mixed by ethanol 672mg, sodium lauryl sulphate 5mg, PEG400 21mg, propylene glycol 49mg and pure water;
Described compound Chinese medicine powder is prepared as follows and forms:
1) get Radix Platycodonis 100g, Cortex Moutan 80g, Radix Saposhnikoviae 80g, Fructus Forsythiae 70g and Radix Puerariae 50g, put in pulverizer and pulverize, take out and be laid into 400cm2, irradiate 10 minutes under ultraviolet, uitraviolet intensity is 2000uW/cm2; Then use the pure water of 2L as solvent, 60 ℃ are hydrolyzed 1 day, filter and collect filtrate; Filtrate is placed in vacuum decker, is concentrated in vacuo to 1/5th of filtrate volume, obtain concentrated solution;
2) take Sargassum 100g, Radix Scutellariae 80g, Radix Rehmanniae 70g, Radix Paeoniae Alba 60g and Radix Glycyrrhizae 50g, mix homogeneously, the decocting that adds 5 times of weight boils 1 hour, filters and collects filtrate, the pH that adjusts filtrate with the hydrochloric acid solution of 1mol/L is 7, then filtrate is condensed into the extractum that density is 1.1g/ml;
3) by step 1) concentrated solution and the step 2 prepared) extractum prepared mixes, and stirs, and is then placed at 70 ℃ after couveuse is dried, and more than being crushed to 200 orders, obtains described compound Chinese medicine powder.
The invention also discloses the preparation technology of above-mentioned liniment.
Usage: powder and solvent, be applied to affected part, parcel lucifuge 4 hours, then 615-645nm red light irradiation affected part is 15 minutes; Once in a week, continuous three weeks.
The main beneficial effect that the present invention obtains is as follows:
Liniment of the present invention adopts Chinese medicine and western medicine set, is equipped with pure Chinese medicine, and the compatibility of each taste Chinese medicine is reasonable, and therapeutic effect is good, have no side effect, and treating both the principal and secondary aspects of a disease, short treating period, acne, is better than 5-ALA liniment of the prior art effectively;
The present invention adopts unique Technology, for different raw materials, adopt different processing modes, select the UV treatment of suitable time and amount of radiation, the effective ingredient in raw material is discharged to greatest extent, the nutritional labeling waste of having avoided single processing mode to cause; And extraction step is simple to operate, be applicable to suitability for industrialized production, possess wide application prospect;
The adjuvant that the present invention selects is reasonable, and pure water is mainly as the solvent of principal agent; Ethanol, as penetrating agent, antiseptic, can increase drug osmotic effect, thereby improves the absorption of medicine, and has certain antisepsis; PEG400 is done cosolvent and stabilizing agent; Sodium lauryl sulphate is done penetrating agent; Propylene glycol has moisturizing, antisepsis.
The specific embodiment
Below employing specific embodiment is made to further explanation to the present invention, but it is not as the restriction to initiative spirit of the present invention.
Embodiment 1
A 5-ALA liniment, it is comprised of powder and solvent two parts, powder is 354mg/ bottle, solvent is 1.5ml/ bottle, during use by the two molten fitting over together; Powder is 5-ALA powder; Solvent (1.5ml) is mixed by ethanol 672mg, sodium lauryl sulphate 5mg, PEG400 21mg, propylene glycol 49mg and pure water; The preparation method of solvent is as follows: ethanol 672mg, sodium lauryl sulphate 5mg, PEG400 21mg, propylene glycol 49mg are added in container, then add appropriate pure water standardize solution to 1.5ml.
Method of application: powder and solvent, be applied to affected part, parcel lucifuge 4 hours, then 615-645nm red light irradiation affected part is 15 minutes; Once in a week, continuous three weeks.
Embodiment 2
A 5-ALA liniment, it is comprised of powder and solvent two parts, powder is 354mg/ bottle, solvent is 1.5ml/ bottle, during use by the two molten fitting over together; Powder is that 5-ALA powder and compound Chinese medicine powder mix according to the weight ratio of 1:1; Solvent (1.5ml) is mixed by ethanol 672mg, sodium lauryl sulphate 5mg, PEG400 21mg, propylene glycol 49mg and pure water; The preparation method of solvent is as follows: ethanol 672mg, sodium lauryl sulphate 5mg, PEG400 21mg, propylene glycol 49mg are added in container, then add appropriate pure water standardize solution to 1.5ml;
Above-mentioned compound Chinese medicine powder is prepared as follows and forms:
1) get Radix Platycodonis 100g, Cortex Moutan 80g, Radix Saposhnikoviae 80g, Fructus Forsythiae 70g and Radix Puerariae 50g, put in pulverizer and pulverize, take out and be laid into 400cm
2, under ultraviolet, irradiating 10 minutes, uitraviolet intensity is 2000uW/cm
2; Then use the pure water of 2L as solvent, 60 ℃ are hydrolyzed 1 day, filter and collect filtrate; Filtrate is placed in vacuum decker, is concentrated in vacuo to 1/5th of filtrate volume, obtain concentrated solution;
2) take Sargassum 100g, Radix Scutellariae 80g, Radix Rehmanniae 70g, Radix Paeoniae Alba 60g and Radix Glycyrrhizae 50g, mix homogeneously, the decocting that adds 5 times of weight boils 1 hour, filters and collects filtrate, the pH that adjusts filtrate with the hydrochloric acid solution of 1mol/L is 7, then filtrate is condensed into the extractum that density is 1.1g/ml;
3) by step 1) concentrated solution and the step 2 prepared) extractum prepared mixes, and stirs, and is then placed at 70 ℃ after couveuse is dried, and more than being crushed to 200 orders, obtains described compound Chinese medicine powder.
Method of application: powder and solvent, be applied to affected part, parcel lucifuge 4 hours, then 615-645nm red light irradiation affected part is 15 minutes; Once in a week, continuous three weeks.
Embodiment 3
The zoology effect of the liniment of embodiment 1 and 2 preparations:
Animal is selected: 60 of new zealand rabbits, and male and female half and half, body weight is 2.2 ± 0.3kg;
Experimental design: select at random 50 rabbit, in every rabbit right in ear side syrinx opening part preserved skin 2cm * 2cm scope, with the even coating 50% oleic acid 0.5mL of syringe, 1 time/d, continuous 2 weeks, after coating the 12nd day, the wide intradermal injection density 10 of auris dextra
9the propionibacterium acnes liquid 200 μ L of individual/mL, and mark in injection place.In the 15th day, evaluation model formational situation, occur that following symptom is modeling success: red swelling of the skin, slightly thick, follicular orifice protuberance is pimple shape, rough surface, that touches is hard like acneform, and microscopy hair follicle surrounding cuticular layer obviously thickens, be full of pink keratinization thing in enlarged areas, chamber, sebaceous gland increases obviously, consistent with mankind's acne symptom.Choose 40 of the successful rabbit of modeling, be divided into model control group, control drug group, 1 group of embodiment, 2 groups of embodiment; 10 of modeling is not blank group.
1 group of administering mode: embodiment: solvent is extracted out with syringe, inject powder, vibration is dissolved it, and the cotton balls (dose 2mL) that soaks full medicinal liquid by suitable size covers affected part completely, then covers lucifuge with the aluminium foil that is greater than cotton balls, immobilization with adhesive tape, after lucifuge 2h, clear water cleans affected part, wipe away dry after, use He-Ne laser therapeutic apparatus (wavelength 632nm, power 150mW/cm
2), optical fiber head is apart from skin lesion 10mm, vertical irradiation, and the about 4mm of spot diameter, irradiates 20min; Weekly, continuous three weeks.2 groups of processing modes of embodiment are with 1 group of embodiment.Model control group: the solvent part of an affected part liniment, simulated light dynamic therapy, 1 time/week, is used in conjunction 3 weeks.Control drug group: affected part is coated with clindamycin and metronidazole liniment, each 1 time sooner or later, is used in conjunction 3 weeks.Concrete therapeutic outcome is in Table 1:
Table 1
Conclusion:
2 groups of therapeutic effect of embodiment 1 and embodiment are remarkable, can significantly improve the size of sebaceous gland and hair follicle, effectively suppressed the generation of acne dermatitis, are better than prior art routine administration; And find, 2 groups of embodiment, therapeutic effect is obviously better than 1 group of embodiment.
Embodiment 4
Transdermal absorption factor test:
Adopt new zealand rabbit, be divided into two groups, 10 every group; With syringe, solvent is extracted out, injected powder, vibration is dissolved it, and the cotton balls that soaks full medicinal liquid by suitable size covers auris dextra medial surface completely, then covers lucifuge with the aluminium foil that is greater than cotton balls, and immobilization with adhesive tape, after lucifuge 2h, detects absorbance; I: (solvent formula of the ALA liniment of U.S.'s listing is (w/w) to external ALA liniment listing product formula: 39.9%-48.8% ethanol, 39.1%-47.8% pure water, 5.9%-7.4% lauryl alcohol, 3.5%-4.3% isopropyl alcohol, 1.5-1.8% Polyethylene Glycol) and II: the transdermal absorption factor measurement result of liniment formula of the present invention (embodiment 2) is as following table 2:
Table 2
| Time (min) | 15 | 30 | 45 | 60 | 90 | 120 |
| (I) transdermal absorption factor (%) | 5.9 | 26.7 | 36.7 | 54.6 | 75.5 | 84.5 |
| (II) transdermal absorption factor (%) | 7.2 | 33.2 | 43.9 | 57 | 76 | 88.5 |
Result of the test shows, the Transdermal absorption situation of two kinds of formulas is all relatively good, and the assimilation effect of the embodiment of the present invention 2 is more better than matched group, and it is rational that the prescription that proves the 5-ALA liniment of the present invention's development forms.
Although, above used general explanation, the specific embodiment and test, the present invention is described in detail, on basis of the present invention, can make some modifications or improvements it, and this will be apparent to those skilled in the art.Therefore, these modifications or improvements, all belong to the scope of protection of present invention without departing from theon the basis of the spirit of the present invention.
Claims (2)
1. a 5-ALA liniment, is characterized in that, described liniment is comprised of powder and solvent two parts, and described powder is 354mg/ bottle, and described solvent is 1.5ml/ bottle, during use by the two molten fitting over together;
Described powder is that 5-ALA powder and compound Chinese medicine powder mix according to the weight ratio of 1:1; Described solvent is mixed by ethanol 672mg, sodium lauryl sulphate 5mg, PEG400 21mg, propylene glycol 49mg and pure water; The preparation method of described solvent is as follows: ethanol 672mg, sodium lauryl sulphate 5mg, PEG400 21mg, propylene glycol 49mg are added in container, then add appropriate pure water standardize solution to 1.5ml;
Described compound Chinese medicine powder is prepared as follows and forms:
1) get Radix Platycodonis 100g, Cortex Moutan 80g, Radix Saposhnikoviae 80g, Fructus Forsythiae 70g and Radix Puerariae 50g, put in pulverizer and pulverize, take out and be laid into 400cm
2, under ultraviolet, irradiating 10 minutes, uitraviolet intensity is 2000 μ W/cm
2; Then use the pure water of 2L as solvent, 60 ℃ are hydrolyzed 1 day, filter and collect filtrate; Filtrate is placed in vacuum decker, is concentrated in vacuo to 1/5th of filtrate volume, obtain concentrated solution;
2) take Sargassum 100g, Radix Scutellariae 80g, Radix Rehmanniae 70g, Radix Paeoniae Alba 60g and Radix Glycyrrhizae 50g, mix homogeneously, the decocting that adds 5 times of weight boils 1 hour, filters and collects filtrate, the pH that adjusts filtrate with the hydrochloric acid solution of 1mol/L is 7, then filtrate is condensed into the extractum that density is 1.1g/ml;
3) by step 1) concentrated solution and the step 2 prepared) extractum prepared mixes, and stirs, and is then placed at 70 ℃ after couveuse is dried, and more than being crushed to 200 orders, obtains described compound Chinese medicine powder.
2. the application of liniment as claimed in claim 1 in preparing the medicine of Acne treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310374599.0A CN103417966B (en) | 2013-08-23 | 2013-08-23 | Hydrochloric acid aminolevulinic acid liniment and preparation technology thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310374599.0A CN103417966B (en) | 2013-08-23 | 2013-08-23 | Hydrochloric acid aminolevulinic acid liniment and preparation technology thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103417966A CN103417966A (en) | 2013-12-04 |
| CN103417966B true CN103417966B (en) | 2014-09-10 |
Family
ID=49643704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310374599.0A Expired - Fee Related CN103417966B (en) | 2013-08-23 | 2013-08-23 | Hydrochloric acid aminolevulinic acid liniment and preparation technology thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103417966B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103816116B (en) * | 2014-03-18 | 2015-07-08 | 翔宇药业股份有限公司 | Medicament for treating skin cancer and preparation method thereof |
| CN103816539B (en) * | 2014-03-18 | 2015-07-22 | 翔宇药业股份有限公司 | Medicinal composition containing aminolevulinic acid |
| CN103860535B (en) * | 2014-03-19 | 2015-09-23 | 翔宇药业股份有限公司 | A kind of 5-ALA liniment |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102716380B (en) * | 2012-07-04 | 2013-10-30 | 甘肃省商业科技研究所 | Compound acne-removal cream and production method thereof |
| CN102827015B (en) * | 2012-09-24 | 2014-07-02 | 南通南京大学材料工程技术研究院 | Preparation method of 5-aminolevulinic acid (ALA) hydrochloride |
-
2013
- 2013-08-23 CN CN201310374599.0A patent/CN103417966B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103417966A (en) | 2013-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105769654A (en) | Anti-sensitivity skin-care composition and application thereof to cosmetics | |
| CN106728457B (en) | Traditional Chinese medicine acne-removing mask | |
| CN104208153B (en) | One kind treats dermopathic Chinese medicine composition and its preparation | |
| CN109394959A (en) | It is a kind of to have effects that repair the Chinese medicine composition of keratoderma and its water extract and fermentation material and application | |
| CN103417966B (en) | Hydrochloric acid aminolevulinic acid liniment and preparation technology thereof | |
| CN107468798A (en) | A kind of composition for treating acne and its preparation method and application | |
| CN104147198A (en) | Traditional Chinese medicine compound for treating papular acne and preparation thereof | |
| CN101983652A (en) | Traditional Chinese medicine for treating scapulohumeral periarthritis | |
| CN104721744A (en) | Pharmaceutical composition with whitening function and preparation method thereof | |
| WO2003061676A1 (en) | Compositions for and method of treatment for skin ailments | |
| CN102784216B (en) | Traditional Tibetan medicine for treating alopecia | |
| CN101904928A (en) | Ointment for treating psoriasis | |
| CN112402268A (en) | Patch type facial mask for preventing and treating acne, preparation method and preparation device | |
| CN103816539B (en) | Medicinal composition containing aminolevulinic acid | |
| CN102793771B (en) | Preparation method of Tibetan drug for treating alopecia | |
| CN104027505A (en) | Method for preparing traditional Chinese medicine facial mask powder for treating pimple | |
| CN103705760A (en) | Suppository preparation method for postpartum perineum pain | |
| CN103316177A (en) | Ointment capable of promoting blood circulation to remove blood stasis, diminishing inflammation and relieving pain and preparation method thereof | |
| CN111329935B (en) | Traditional Chinese medicine freckle-removing composition and preparation method and application thereof | |
| CN106667851A (en) | Traditional Chinese medicine acne removal cream and preparation method thereof | |
| CN101700331B (en) | Bone joiner spray | |
| CN105412395A (en) | Traditional Chinese medicine composition for treating hyperostosis and preparation method thereof | |
| CN107496708B (en) | Traditional Chinese medicine mask for treating acne and preparation method thereof | |
| KR20100105093A (en) | Composition for promoting the differentiation of human mesenchymal stem cell to adipocytic cells | |
| CN103860535B (en) | A kind of 5-ALA liniment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG XIANGYU HEALTH PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LIN FANYOU Effective date: 20140711 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20140711 Address after: 276023 No. 30, Hangzhou Road, Linyi economic and Technological Development Zone, Linyi, Shandong Applicant after: Shandong Xiangyu Health Pharmaceutical Co., Ltd. Address before: 276023 Beijing road Shandong Linyi Province, Linyi City Economic Development Zone No. 30 Shandong Xiangyu Health Pharmaceutical Co. Ltd. Applicant before: Lin Fanyou |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: XIANGYU PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: SHANDONG XIANGYU HEALTH PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 276023 No. 30, Hangzhou Road, Linyi economic and Technological Development Zone, Linyi, Shandong Patentee after: Xiang Yu Pharmaceutical limited company Address before: 276023 No. 30, Hangzhou Road, Linyi economic and Technological Development Zone, Linyi, Shandong Patentee before: Shandong Xiangyu Health Pharmaceutical Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140910 Termination date: 20190823 |